Technology Commercialization Office

Showing 6 result(s) for "Drugs/Pharmaceuticals"



A new class of small-molecule cyclin D1 ablative agents based on troglitazone (TG) that repress intracellular cyclin D1 levels.

Development of thiazolidinedione (TZD), OSU-CG12, as a novel energy restriction-mimetic agent for cancer therapy and chemo-prevention.

A set of novel DNA methylation inhibitors that reduce DNA methylation by small molecule agents.

Estrogen Receptor Beta Agonists for the treatment of breast, colon, and prostate cancers as well as inflammatory diseases.

A new strategy for using androgen receptor ablative agents has been developed for prostate cancer therapy.

An anti-tumor agent developed from indol-3-carbinol, a naturally occurring phytochemical in cruciferous vegetables.